Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors-Reference-Cited by-同舟云学术

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

Published:2016-10-04 Issue:1 Volume:9 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Sun Yongkun,Niu Wei,Du Feng,Du Chunxia,Li Shuting,Wang Jinwan,Li Li,Wang Fengqing,Hao Yu,Li Chuan,Chi Yihebali

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/s13045-016-0332-8.pdf

Reference23 articles.

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70.

3. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23(5):965–72.

4. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25–35.

5. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658–67.

Cited by 327 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer;Chemical Engineering Journal;2024-10

2. Unveiling promising targets in gastric cancer therapy: A comprehensive review;Molecular Therapy: Oncology;2024-09

3. Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress;Cell Death Discovery;2024-08-08

4. REThinking the role of the RET oncogene in breast cancer;Frontiers in Oncology;2024-08-01

5. A Concerning Case of Severe Gastritis With Gastrointestinal Protein Loss;Gastroenterology;2024-08